This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Heimann, R. Articles by Hellman, S. Search for Related Content PubMed Articles by Heimann, R. Articles by Hellman, S.

The Relationship between nm23, Angiogenesis, and the Metastatic Proclivity of Node-negative Breast Cancer¹

Department of Radiation and Cellular Oncology [R. H., S. H.] and Department of Surgery, Division of the Biological Sciences [D. J. F.], The Pritzker School of Medicine, The University of Chicago, Chicago, Illinois 60637

Distant metastases are the major cause of morbidity and mortality in women with breast cancer. The prediction of this metastatic proclivity is essential in determining prognosis and should allow an appropriate choice of therapy. A critical look at the metastatic process and its phenotypic expression offers an opportunity to identify some of the important events in the process that may relate to prognosis, with the goal of identifying those patients with occult metastases and also sparing systemic treatment in those patients whose tumors have not developed the capacity for distant spread. To evaluate the significance of nm23 and angiogenesis in the metastatic cascade, we used archival material from 163 node-negative breast cancer patients who had a median follow-up of 14 years. All patients underwent mastectomy and received no adjuvant chemotherapy or hormone or radiation therapy. Immunohistochemistry was used to detect nm23-H1 expression, whereas angiogenesis was determined by microvessel count (MVC). We found the 15-year disease-free survival (DFS) to be significantly better in patients with high nm23 compared with low nm23 (91% compared with 70%, P = 0.008). Low MVC is associated with excellent (92%) long-term DFS. In those patients with high MVC, high nm23 allows the identification of a subgroup with significantly higher DFS (90% compared with 66%, P = 0.02). Among high nuclear grade tumors, if nm23 is high, the DFS is significantly better (89% compared with 68%, P = 0.03). Thus, nm23 is still associated with excellent survival, even when there is unfavorable angiogenesis or nuclear grade. Multivariate analysis confirms that nm23 and MVC are important prognostic factors. High MVC appears necessary but not sufficient for metastasis to occur, whereas low nm23 may further contribute to metastatic progression. Both nm23 and MVC contribute valuable information in characterizing the malignant phenotype.

¹ This research was partially supported by a grant from the Sidney Kimmel Foundation for Cancer Research.

² To whom requests for reprints should be addressed, at Department of Radiation and Cellular Oncology, The University of Chicago, MC 9006, 5758 South Maryland Avenue, Chicago, IL 60637. Phone: (773) 702-5194; Fax: (773) 834-7340; E-mail: heimann@rover.uchicago.edu.

Received 3/ 4/98. Accepted 5/14/98.

This article has been cited by other articles:

				P. S. Steeg, C. E. Horak, and K. D. Miller Clinical-Translational Approaches to the Nm23-H1 Metastasis Suppressor Clin. Cancer Res., August 15, 2008; 14(16): 5006 - 5012. [Abstract] [Full Text] [PDF]

				D. C. Lee, Y. K. Kang, W. H. Kim, Y. J. Jang, D. J. Kim, I. Y. Park, B. H. Sohn, H. A. Sohn, H. G. Lee, J. S. Lim, et al. Functional and Clinical Evidence for NDRG2 as a Candidate Suppressor of Liver Cancer Metastasis Cancer Res., June 1, 2008; 68(11): 4210 - 4220. [Abstract] [Full Text] [PDF]

				P. S. Steeg PERSPECTIVES ON CLASSIC ARTICLES: Metastasis Suppressor Genes J Natl Cancer Inst, March 17, 2004; 96(6): E4 - E4. [Full Text]

				A N J Graham, P Maxwell, K Mulholland, A H Patterson, N Anderson, K G McManus, H Bharucha, and J A McGuigan Increased nm23 immunoreactivity is associated with selective inhibition of systemic tumour cell dissemination J. Clin. Pathol., March 1, 2002; 55(3): 184 - 189. [Abstract] [Full Text] [PDF]

				Y.-H. Tseng, D. Vicent, J. Zhu, Y. Niu, A. Adeyinka, J. S. Moyers, P. H. Watson, and C. R. Kahn Regulation of Growth and Tumorigenicity of Breast Cancer Cells by the Low Molecular Weight GTPase Rad and Nm23 Cancer Res., March 1, 2001; 61(5): 2071 - 2079. [Abstract] [Full Text]

				M. T. Hartsough, S. E. Clare, M. Mair, A. G. Elkahloun, D. Sgroi, C. K. Osborne, G. Clark, and P. S. Steeg Elevation of Breast Carcinoma Nm23-H1 Metastasis Suppressor Gene Expression and Reduced Motility by DNA Methylation Inhibition Cancer Res., March 1, 2001; 61(5): 2320 - 2327. [Abstract] [Full Text]

				B. A. Yoshida, M. M. Sokoloff, D. R. Welch, and C. W. Rinker-Schaeffer Metastasis-Suppressor Genes: a Review and Perspective on an Emerging Field J Natl Cancer Inst, November 1, 2000; 92(21): 1717 - 1730. [Abstract] [Full Text] [PDF]

				R. Heimann and S. Hellman Clinical Progression of Breast Cancer Malignant Behavior: What to Expect and When to Expect it J. Clin. Oncol., February 1, 2000; 18(3): 591 - 591. [Abstract] [Full Text] [PDF]

				R. Heimann, F. Lan, R. McBride, and S. Hellman Separating Favorable from Unfavorable Prognostic Markers in Breast Cancer: The Role of E-Cadherin Cancer Res., January 1, 2000; 60(2): 298 - 304. [Abstract] [Full Text]